Fixed-dose combination (FDC) products represent a widely accepted
approach to type 2 diabetes treatment, given that monotherapies
sometimes fail to meet the treatment-targets obtaining a sustained
reduction in micro-and macrovascular complications. Saxagliptin
(SAXA)/metformin (MET) FDC tablets can be used either alone or in
combination with glyburide, thiazolidinediones, or insulin. It has been
proven that the SAXA/MET combination leads to a significant improvement
in glycemic control compared to placebo in patients with type 2 diabetes
that is inadequately controlled with MET alone. In addition, this FDC
has been proven to be safe for people with diabetes mellitus and
established cardiovascular disease, elderly patients, and patients with
impaired renal function (>30 mL/minute), with dosage modification.
Patient compliance, adherence, and persistence to the therapeutic
regimen has been shown to be very good, while the titration of each
compound according to the patient’s profile is easy, given the
availability of different formulations. The SAXA/MET FDC is a
patient-friendly, dosage-flexible, and hypoglycemia-safe regimen with
very few adverse events and a neutral or even favorable effect on body
weight. It achieves significant glycosylated hemoglobin A(1c) reduction
helping the patient to achieve his/her individual glycemic goals
